First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Recruiting

Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Sponsor:

Relay Therapeutics, Inc.

Code:

NCT05216432

Conditions

PIK3CA Mutation

Solid Tumor, Adult

HER2-negative Breast Cancer

Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RLY-2608

Fulvestrant

Palbociclib 125mg

Ribociclib 400mg

Ribociclib 600mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Relay Therapeutics, Inc. on 2025-01-29.